Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606560 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTSIRT2SIRT1KDM4E | |
| SCHEMBL5606901 | 0.83 | MEN1 (0.49) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL5606898 | 0.83 | MEN1 (0.49) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL5606098 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL5606100 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6297741 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6297740 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL6431456 | 0.77 | P2RX7 (0.46) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL6431453 | 0.77 | P2RX7 (0.46) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL6431775 | 0.76 | HDAC1 (0.47) | KMT2AMEN1NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | claimed |
| EP-0929528-B1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2006-03-09 | — | — | US | disclosed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885MAPT 2995/4885SIRT2 1574/4885 |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885MAPT 2995/4885SIRT2 1574/4885 |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885MAPT 2995/4885SIRT2 1574/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ALDH1A1 1434/4885MAPT 2671/4885SIRT2 1645/4885 |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | DRD2, OPRL1, SLC6A3 | ALDH1A1 1049/4885MAPT 2035/4885SIRT2 2487/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | ALDH1A1 534/4885MAPT 1996/4885SIRT2 3391/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885MAPT 2995/4885SIRT2 1574/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885MAPT 2995/4885SIRT2 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.